DATE : 2014-08-21

 

Bristol-Myers Squibb (BMY) and Celgene (CELG) announced the establishment of a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of a combination regimen ofBristol-Myers Squibb's investigational PD-1 immune checkpoint inhibitor, OPDIVO and Celgene's nab technology-based chemotherapy ABRAXANE in a Phase I study. Multiple tumor types will be explored in the study including HER-2 negative metastatic breast cancer, pancreatic cancer and non-small cell lung cancer. The proprietary name OPDIVO has been proposed in the U.S. and other countries, but remains subject to health authority approval.

The study, which is expected to begin in 4Q14, will be conducted by Celgene. Patients with HER-2 negative breast cancer will be treated with ABRAXANE and OPDIVO, patients with NSCLC will be treated with the combination of ABRAXANE, carboplatin and OPDIVO, and patients with pancreatic adenocarcinoma will be treated with ABRAXANE, gemcitabine and OPDIVO.

Additional details of the collaboration were not disclosed.

 

SOURCE Theflyonthewall.com